Neuron-specific enolase is unaltered whereas S100B is elevated in serum of patients with schizophrenia--original research and meta-analysis.

Abstract

Previous studies reported altered levels of the astrocytic marker S100B in schizophrenia. To clarify mechanisms, we measured weekly serum levels of S100B together with the neuronal marker neuron-specific enolase in 20 patients with schizophrenia and 19 age- and gender-matched control subjects. S100B was elevated at admission and discharge in schizophrenic patients compared with control subjects, whereas there were no significant differences for neuron-specific enolase. Treatment had no impact on either S100B or neuron-specific enolase. A systematic, quantitative meta-analysis of all published studies involving 380 patients and 358 control subjects revealed elevated serum S100B in schizophrenia without any effect of antipsychotic treatment. Results suggest that increases of serum S100B are related to active secretion of S100B by astrocytes in combination with blood-brain barrier dysfunction in schizophrenia.

• Authors: Matthias L Schroeter, Hashim Abdul-Khaliq, Michael Krebs, Albert Diefenbacher, Ingolf E Blasig
• Journal: Psychiatry research (Psychiatry Res) Vol. 167 Issue 1-2 Pg. 66-72 (May 15 2009) ISSN: 0165-1781 [Print] Ireland
• PMID: 19375171 (Publication Type: Comparative Study, Journal Article, Meta-Analysis)

Chemical References

• Nerve Growth Factors
• S100 Calcium Binding Protein beta Subunit
• S100 Proteins
• S100B protein, human
• Phosphopyruvate Hydratase

Topics

• Adult
• Astrocytes (metabolism)
• Blood-Brain Barrier
• Female
• Humans
• Male
• Middle Aged
• Nerve Growth Factors (blood)
• Neurons (metabolism)
• Patient Admission
• Patient Discharge
• Phosphopyruvate Hydratase (blood)
• S100 Calcium Binding Protein beta Subunit
• S100 Proteins (blood, metabolism)
• Schizophrenia (blood, diagnosis)
• Schizophrenic Psychology